Home » Topics » BioWorld Science

BioWorld Science
RSS

SwanBio begins natural history study of adrenomyeloneuropathy to support SBT-101 development

July 1, 2021

New antifungals identified at Wigen Biomedicine Technology

July 1, 2021

Saniona begins phase I trial of SAN-711 for neuropathic disorders

June 30, 2021

Alnylam initiates phase II study of zilebesiran for mild to moderate hypertension

June 30, 2021

HZN-7734 enters phase II study for SLE

June 30, 2021

FDA approves IND for phase I/II trial of ExoFlo for mild to moderate COVID-19

June 30, 2021

Endpoints not met in phase II trial of ANG-3777 in COVID-19-associated pneumonia

June 30, 2021

Altimmune discontinues AdCOVID development, updates T-COVID progress

June 30, 2021

Novel miRNAs found with prognostic value in heart failure

June 30, 2021

Dosing begins in phase Ib/II study of TTI-621 with doxorubicin in leiomyosarcoma

June 30, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...